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Abstract
Background: There is paucity of data from India on the impact of HIV related immunosuppression in response to TB
treatment and mortality among HIV infected TB patients. We assessed the TB treatment outcome and mortality in a cohort
of HIV infected TB patients treated with intermittent short course chemotherapy under TB control programme in a high HIV
prevalent district of south India.
Methodology/ Findings: Among 3798 TB patients registered for treatment in Mysore district from July 2007 to June 2008,
281 HIV infected patients formed the study group. The socio-demographic and treatment related data of these patients was
obtained from TB and HIV programme records and patient interviews 19 months after TB treatment initiation by field
investigators. Treatment success rate of 281 patients was 75% while in smear positive pulmonary tuberculosis cases it was
62%, attributable to defaults (16%) and deaths (19%). Only 2 patients had treatment failure. Overall, 83 (30%) patients were
reported dead; 26 while on treatment and 57 after TB treatment. Association of treatment related factors with treatment
outcome and survival status was studied through logistic regression analysis. Factors significantly associated with
‘unfavourable outcome’ were disease classification as Pulmonary [aOR-1.96, CI (1.02–3.77)], type of patient as retreatment
[aOR-4.78, CI (2.12–10.76)], and non initiation of ART [aOR-4.90, CI (1.85–12.96)]. Factors associated with ‘Death’ were non
initiation of ART [aOR-2.80, CI (1.15–6.81)] and CPT [aOR-3.46, CI (1.47–8.14)].
Conclusion: Despite the treatment success of 75% the high mortality (30%) in the study group is a matter of concern and
needs immediate intervention. Non initiation of ART has emerged as a high risk factor for unfavourable treatment outcome
and mortality. These findings underscore the importance of expanding and improving delivery of ART services as a priority
and reconsideration of the programme guidelines for ART initiation in HIV infected TB patients.
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Introduction
TB is the commonest Opportunistic Infection (OI) among HIV
infected patients, particularly in the developing countries [1,2].
HIV fuels progression to active disease in people infected with TB
with an annual risk of 5–15% compared with 10–20% life time
risk among non HIV infected patients [3]. The HIV/AIDS
epidemic has a dramatic impact on the epidemiology of
tuberculosis. This has increased the global tuberculosis burden
[4] especially in populations where HIV is common and where the
prevalence of tuberculosis infection is high [5,6]. The overlap of
HIV and TB epidemics is particularly striking in south East Asian
countries. HIV prevalence among TB patients is higher than in
general population which has been documented in several studies
from different parts of the country [7].
India has the world’s highest burden of tuberculosis, with 2
million (1.6–2.4 million) incident cases, an estimated 6.4% (3.9–
9.8%) are HIV infected and has 2.3 million persons living with
HIV/AIDS [8,9]. The policy of co-ordinated TB and HIV-AIDS
controlprogrammeactivitiesmakesearlydetectionofHIVinfection
among TB patients possible and also offers an opportunity to
promptly link patients to HIV care interventions. We conducted a
study in2007 in two districts ofsouth Indiato evaluate thefeasibility
of provider initiated HIV testing and counselling (PITC) of TB
patients and to assess the efficiency of linkage of HIV sero-positives
for care and treatment [10]. This study provided the first evidence
from India on the successful implementation of PITC services for
TB patients by the general health care system in high prevalence
settings. However, the linkage to life saving Anti Retroviral
Treatment (ART) services was found lacking.
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26Tuberculosis is still the leading cause of mortality among HIV
infected patients and this accounts for one third of the deaths due
to AIDS worldwide [11,12]. Striking impact of HIV infection on
mortality among TB patients has been reported from several
studies [13–17]. Though, mortality rate from HIV associated TB
in developing countries is high, it is not clear whether it is due to
failure of anti TB treatment or complications of HIV [15].
There is paucity of data from India on the impact of HIV
related immunosuppression on response to TB treatment and
subsequent mortality [18]. This information is essential for
implementing interventions to improve the survival of HIV
infected TB patients. We followed up the cohort of HIV infected
TB patients of our earlier study after their treatment with
Intermittent Short Course Chemotherapy (SCC) regimen under
the TB control programme. The primary objective was to assess
their TB treatment outcomes and mortality after treatment. The
secondary objective was to identify treatment related factors
associated with TB treatment outcome and survival status.
Methods
Ethics statement
The purpose of seeking information was explicitly told to the
patient. Individual informed verbal consent was obtained prior to
interview as there was no intervention / procedure involved.
Patient’s consent to participate was recorded on the study format.
Data collected from patients and records were confidentially
maintained by the study staff. The study procedures including
verbal consent from patient were approved by the ethics
committee of the National Tuberculosis Institute, Bangalore.
Approval and financial support for the research was granted by the
Ministry of Health and Family Welfare, Government of India.
Setting
The study was conducted in Mysore district of Karnataka state
(population 2.8 million). The district has been classified as high
priority for HIV interventions by National AIDS Control
Organization (NACO) on the basis of consistently having .1%
HIV seroprevalence during sentinel surveillance at antenatal
clinics [19]. In the district, tuberculosis control programme
services are available through a decentralized network of primary
health care facilities which provide general health services
including quality-assured smear microscopy and directly observed
treatment through health facilities and community DOT provid-
ers. All TB patients initiated on treatment were registered at the
six sub district level TB programme management units. Voluntary
HIV counselling and testing services were offered through
National AIDS Control Programme (NACP) - supported network
of 27 integrated counselling and testing centres (ICTC). Free
antiretroviral treatment (ART) was provided at one ART centre,
where HIV-infected patients are screened for ART eligibility and
offered HIV treatment and care. These service delivery sites under
NACP follow the national guidelines for counselling, testing, care
and treatment of HIV-infected patients [20].
Design and Definitions
In this observational study a cohort of TB patients registered for
treatment in the district was followed up prospectively. The end
points assessed were TB treatment outcomes and survival status
after treatment period of HIV infected TB patients in the cohort.
The TB treatment outcomes were assessed as ‘favourable
outcome’ (cure and treatment completed) and ‘unfavourable
outcome’ (default, dead, failure). Retreatment cases were those
having history of previous TB treatment of .1month. Treatment
regularity is defined as patient not missing any dose either in the
intensive or continuation phase of treatment.
Study group
In the cohort of 3798 TB patients registered under the Revised
National Tuberculosis control Programme (RNTCP) from 1
st July
2007 to 30
th June 2008, in the district, 72% were aware of their
HIV status and of them 281 patients identified as HIV infected
during our earlier study constituted the study group. These
patients were treated with intermittent SCC regimen administered
under DOT following the programme guidelines [21]. After an
average period of one and half year of TB treatment initiation, the
study group was contacted and interviewed to collect the required
information.
Data collection and analysis
The data sources for the study were RNTCP and NACP
records and details from the patient interviews. Patients were
interviewed in local language by trained field investigators using a
pre-tested questionnaire. To ensure adequate coverage minimum
three attempts were made to approach the patients.
The line list of the study cohort was available from the earlier
study. This line list elaborating details regarding TB treatment,
referral to ICTC and linkage to ART was also referred to abstract
the relevant information to the format designed for the study.
The Study format for recording individual patient details had
the following information from:
N TB treatment card. Disease classification, history of
previous TB treatment, type of patient, treatment regularity
and treatment outcome.
N ART center records. Pre ART assessment, ART and
Cotrimaxozole prophylactic treatment (CPT) initiation.
N Patient interview. Socio-demographic profile, previous TB
treatment, HIV status of the spouse, linkage to ART center,
pre ART assessment, ART and CPT initiation and history of
OIs.
In addition, the time, place and cause of death of patients
reported dead were obtained from reliable informants well
acquainted with the patient.
Data collection was initiated in March 2009 and completed in
March 2010.
Data analysis
Data management and analysis was done using Microsoft
Access 2002 and SPSS version 15.0 after checking for complete-
ness and consistency. The categorical variables are described as
numbers (%) and continuous variables as Mean [Standard
Deviation (SD)] or Median [Inter Quartile Range (IQR)]. The
categorical variables were assessed using Pearson chi-square test
and calculating Odds Ratio (OR) with corresponding 95%
Confidence Interval. Medians were compared using Mann
Whitney Test.
The treatment related variables of patients with ‘favourable’
and ‘unfavourable’ treatment outcomes as well as of those
‘dead’ and ‘survived’ were compared initially through
univariate analysis to identify factors associated with ‘treatment
outcome’ and ‘survival status’. Logistic regression analysis was
then done to estimate the independent effect of the variables that
were significantly associated. Variables yielding p values,0.1 in
univariate analysis were included in the logistic regression model.
A backward stepwise elimination procedure based on the
likelihood statistics (using probability of 0.1 for removal and 0.05
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associated with treatment outcome and survival status. Statistical
tests were carried out at 5% level of significance.
Results
The study group of 281 HIV infected TB patients was followed
up prospectively after an average period of 18.9 months from the
TB treatment initiation. Of these patients, 176 (63%) could be
interviewed and 83 (30%) were reported dead (figure 1).
Personal and socio-demographic profile of patients
interviewed (Table 1)
The mean age of patients interviewed was 35 yrs (SD-9.83) –
males 36 and females 33 years and 81% were in the age group of
15–44 yrs. Majority (71%) of the patients were males. Of the 143
(81%) married patients, information on HIV status of the spouse
was available for 108 (76%) and of these, 61% were HIV sero-
positive (not on table). Two thirds of the patients were literate and
employed. Twenty nine percent of patients were currently
unemployed due to illness as stated by 46 (90%) patients. The
Mean duration of unemployment was 9 months ranging from 1–
36 months (not on table). History of alcoholism and smoking was
given by 55% and 48% of the patients respectively.
Disease Classification and CD4 count of the study group
(Table 2)
Fifty percent of 281 patients had pulmonary and the rest had
ExtrapulmonaryTB.Of thosewithpulmonaryTB,55%were smear
positive. Among the 63 smear negatives 6 had disseminated form of
tuberculosis. The commonest form of Extra Pulmonary TB was
lymph node involvement (34%) followed by pleural effusion (28%).
CD4 count at treatment initiation was available for 208 TB
patients and the median CD4 count was 117/mm
3 (IQR 64.5–
218.25). In pulmonary TB patients it was 118/mm
3 while in those
with extra pulmonary TB it was 116/mm
3.
TB treatment outcome
The treatment success rate of smear positive patients was 62%
(Table 3). The low success rate was mainly due to ‘death’ (19%)
and ‘defaults’ (16%) as only 2 (3%) patients had ‘treatment failure’.
The treatment success of the study group was 75%, again
attributable to 15% defaults and 9% deaths. Of the 41 patients
who defaulted from treatment 26 (63%) died subsequently.
The treatment related variables considered for comparison
between ‘unfavourable’ and ‘favourable’ outcome were disease
classification, sputum smear status in pulmonary TB patients, type of patient,
treatment regularity , initial CD4 count and initiation of ART & CPT
(Table 4).
‘Retreatment cases’ had a significantly higher probability of
having ‘unfavourable’ treatment outcome as compared to ‘New
Cases’ [OR-4.04, CI (1.96–8.35). Pulmonary TB was also
identified as a potential risk factor for ‘unfavourable outcome’
[OR 2.46, CI (1.35–4.53)]. Non initiation of ART [OR 9.12, (CI
(4.48–18.88)) and of CPT [OR 6.65, (CI 3.53–12.61)] was
significantly associated with ‘unfavourable’ outcome. The median
CD4 count for patients with ‘unfavourable’ and ‘favourable’
treatment outcome was 118/mm
3 (IQR 66.5–219) and 117.5/
mm
3 (IQR 64.5–218.3) respectively (not on table). Irrespective of
the availability of CD4 count or eligibility for ART overall, 157
(56%) patients in the study group were initiated on ART. Sixty
percent of them were initiated on ART during TB treatment (6%
within 15 days and 54% after .15 days of TB treatment initiation)
while, 19% received ART prior to TB treatment and 21% after
completion of TB treatment.
The proportion of patients with CD4 count of #350/mm
3 did
not differ significantly between the two outcome groups. The CD4
count was either not done or information was not available in any
of the ART records for 73 (26%) HIV infected TB patients and
none of these patients received ART. However, of these 73, 36%
of patients had extra pulmonary tuberculosis and were thus eligible
for ART. In the remaining 208 patients with CD4 count, 195
(94%) were eligible for ART as per the NACO guidelines (181
having CD4 count #350/mm
3 and 14 with .350/mm
3 but
having Extra pulmonary TB), but of the eligible, only 157 patients
received ART (not on table).
In the logistic regression analysis factors independently
associated with ‘unfavourable’ outcome were disease classification
as ‘Pulmonary’ [aOR-1.96, CI (1.02–3.77)], type of patient as
‘retreatment’ [aOR-4.78, CI (2.12–10.76)], and ‘not initiated
on ART’ [aOR-4.90, CI (1.85–12.96)].
Figure 1. Interview coverage of the study group.
doi:10.1371/journal.pone.0021008.g001
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Survival status 19 months after TB treatment initiation revealed
that overall, 83 patients were reported dead; 26 while on treatment
and 57 after treatment. The median survival period was the time in
months between date of TB treatment initiation and the date of
death which was 7.3 months (Median days 219, IQR 139–350).
Treatment related factors of ‘dead’ and ‘survived’ patients
considered for comparison were similar to those for ‘treatment
outcome’(Table5).Diseaseclassificationas‘pulmonary TB’[( OR
2.21, CI (1.26–3.88)], type as ‘retreatment cases’ [OR 2.05, CI
(1.01–4.18)] and ‘treatment irregularity’ [OR 2.07, CI (1.14–
3.78)] were potential risk factors for death. Proportion of patients
with CD4 count of #200/mm
3 did not differ significantly between
the two groups. The probability of ‘death’ was significantly higher
among patients ‘not initiated on ART’ [OR 7.75, CI (4.12–
14.71)] or with ‘CPT’ [OR 7.76, CI (4.22–14.85)]. Favourable TB
treatment outcome at the end of treatment period was 36% for the
‘dead’ compared to 92% in the ‘survived’ group. (p=0.00). The
median CD4 count of ‘dead’ and ‘survived’ patients was 137.5/
mm
3 (IQR 63–199.25) and 116/mm
3 (IQR 9.25–321.75) respec-
tively with no significant difference between the two.
In the logistic regression analysis the treatment related factors
independently associated with death were ‘non initiation ART’
[aOR-2.80, CI (1.15–6.81)] and of ‘CPT’ [aOR-3.46, CI (1.47–
8.14)] (Table 6).
Discussion
We evaluated the treatment outcome and survival status 19
months after TB treatment initiation of a cohort of HIV infected
TB patients from a high HIV prevalent district of South India.
Only 63% of the patients could be interviewed. The main reason
for attrition in the coverage was a high proportion of deaths.
Patient profile revealed that majority (81%) were in the socio-
economically productive age group of 15–44 yrs and were
married. A high proportion (61%) of spouses being infected with
HIV reemphasises the importance of disclosing HIV status of the
patient to the spouse at the post-test counselling and the necessity
for routinely monitoring HIV status of the spouse. This also gives a
unique opportunity for positive prevention in a high proportion
(about 40%) of couples discordant for HIV by reinforcing their
awareness on precautions to be taken to prevent transmission of
infection. The current unemployment due to illness in one third of
the patients in the economically productive age group is likely to
affect the families already in the lower socio-economic strata.
More than half of the patients were habituated to alcohol and
smoking indicates their vulnerability to undesirable habits.
Pulmonary and extra pulmonary TB occurred with same
frequency in the cohort in contrast to other reported studies,
wherein higher proportion (50–72%) of HIV infected TB patients
had extra pulmonary TB [22–25]. The probable reason for this
Table 1. Socio-demographic profile of HIV infected TB
patients interviewed N=176.
Profile Numbers %
Age group
,15 3 2
15–44 143 81
45–64 29 16
65 1 1
Gender
Male 125 71
Female 51 29
Marital status
Married 143* 81
Unmarried 33 19
Literacy
Literate 106 60
Illiterate 70 40
Current employment status
Employed 105 60
Unemployed 51 29
Others (housewives, pensioners,
dependents and students)
20 11
Employment**
Labourer 55 31
Semi skilled workers 27 15
Drivers 22 13
Petty business 21 12
Agriculturist 6 3
Professionals 5 3
Others 19 9
Residence
Rural 87 49
Urban 70 40
Semi-urban 19 11
Habits
Alcohol 96 55
Smoking 84 48
*includes separated (10), widowed (27).
**For those employed (105).
doi:10.1371/journal.pone.0021008.t001
Table 2. Disease Classification and CD4 counts in HIV
infected TB patients N=281.
Classification CD4 count/mm3
Pulmonary
No. of
patients
Available
for
Median
(IQR)
Smear positive 77 50 140 (62.75–225)
Smear negative 63* 45 116 (72–171)
Total 141** 95 118 (67.5–207.5)
Extrapulmonary
Lymph node 48 38 109.5 (58.25–221.2)
Pleural effusion 39 29 153 (83–249)
Abdominal 23 22 91 (56–163.75)
TBM 17 13 109 (79–218)
Skin & Spine 2 2 111.5 (103.25–
119.75)
Site not recorded 11 9 106 (69.5–290.5)
Total 140 113 116 (62–219)
IQR – Inter Quartile Range.
*Six smear negative patients had milliary tuberculosis and their median CD4
count was 120. (95–124).
**One smear status not available.
doi:10.1371/journal.pone.0021008.t002
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cases by the peripheral health centres due to limited diagnostic
facilities. Lymph node was the commonest site involved as
observed in previous studies too [24,26].
Majority (73%) of the 208 patients in the study group had a
CD4 count of ,200/mm
3 indicating progressive immunodefi-
ciency. Manifestation of extra pulmonary TB in HIV sero-
positives denotes a greater degree of immunosuppression.
However, as also reported in earlier studies, the median CD4
count in patients with various forms of extra pulmonary TB
though lower than in pulmonary TB did not differ significantly,
suggesting that clinical presentation of tuberculosis did not
correlate with CD4 count [23,27,28]. In contrast, Brenda et.al
have reported a progressive increase in the frequency of extra
pulmonary TB as CD4 cell count decreases suggesting that CD4
cells play a major role in limiting the severity of TB [26].
The treatment success of smear positive HIV infected TB
patients treated with intermittent SCC regimens in our study was
lower than that in TB patients irrespective of HIV status reported
by the programme for the district during the corresponding period
Table 3. Treatment outcomes of HIV infected TB patients according to Disease classification N=281.
Treatment Outcome Favourable Outcome Unfavourable Outcome Total
Classification Cured Treatment Completed Default Failure Dead
Pulmonary N=141
Smear positive 42 (54) 6 (8) 12 (16) 2 (3) 15 (19) 77
Smear negative - 47 (75) 12 (19) - 04 (6) 63
Smear status not available - - - - 1 1
Sub total 42 (30) 53 (38) 24 (17) 2(1) 20 (14) 141
Extrapulmonary N=140 - 117 (83) 17 (12) - 06 (4) 140
Total 42 (15) 170 (60) 41 (15) 2 (1) 26 (9) 281
( ) Percentage.
doi:10.1371/journal.pone.0021008.t003
Table 4. Univariate analysis of the factors associated with TB treatment outcomes (N=281).
Factors
Unfavourable
Outcome
(N=69)
Favourable
Outcome
(N=212) p value
OR
(95% CI)
Disease classification
Pulmonary 46 95 2.46
Extra Pulmonary 23 117 0.002 (1.35–4.53)
Sputum smear status*
Smear positive 29 48 1.77
Smear negative 16 47 0.122 (0.80–3.94)
Type of patient
Retreatment 22 22 4.04
New 47 190 0.000 (1.96–8.35)
Regularity of treatment**
Irregular 40 110 1.63
Regular 21 94 0.107 (0.86–3.09)
Baseline CD4 count /mm3
@
#350 24 157 0.80
.350 4 23 0.825 (0.26–3.29)
ART initiation
Not initiated 56 68 9.12
Initiated 13 144 0.000 (4.48–18.88)
CPT provision
Not given 46 49 6.65
Given 23 163 0.000 (3.53–12.61)
OR - Odds Ratio, CI- Confidence interval.
*Smear status is given only for those with pulmonary TB. Smear status not available for one patient.
**Excludes 16 patients for whom treatment cards were not available (8 each in unfavourable & favourable outcome).
@CD4 count was not available for 32 and 41 patients with favourable and unfavourable treatment outcome respectively.
doi:10.1371/journal.pone.0021008.t004
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to 19% deaths and 15% defaults. Favourable response of 72% has
been reported from south India among culture positive pulmonary
TB cases with HIV treated with intermittent SCC [18]. Treatment
completion rate of 65–73% with SCC among HIV infected TB
patients has also been reported from West Africa, which was
mainly due to high mortality [13]. The high default rate
observed in our cohort could perhaps be due to patients stop
attending for treatment due to ill health or other reasons like work
commitment , alcoholism etc. and requires further studies.
In the logistic regression analysis Retreatment cases were
found to be associated with unfavourable treatment outcome.
Table 5. Univariate analysis of the treatment related factors associated with survival status (N=281).
Factors Dead (N=83) Survived (N=83) P value OR (95% CI)
Disease classification
Pulmonary 53 88 2.21
Extrapulmonary 30 110 0.002 (1.26–3.88)
Smear status*
Smear positive 32 45 1.53
Smear negative 20 43 0.23 (0.72–3.26)
Type of patient
Retreatment 19 25 2.05
New 64 173 0.03 (1.01–4.18)
Regularity of treatment**
Irregular 53** 97** 2.07
Regular 24 91 0.01 (1.14–3.78)
Baseline CD4 count /mm
3#
#200 23 129 0.59
.200 13 43 0.17 (0.26–1.35)
ART initiation
Not initiated 64 60 7.75
Initiated 19 138 0.000 (4.12–14.71)
CPT provision
CPT not given 55 40 7.76
CPT given 28 158 0.000 (4.22–14.35)
TB treatment outcome
Unfavourable 53 16 20.1
Favourable 30 182 0.000 (9.70–42.10)
OR - Odds Ratio, CI- Confidence interval.
*Smear status is given only for those with pulmonary TB. Smear status not available for one patient,
**Excludes 16 patients for whom treatment cards were not available (6 in dead and 10 in survived).
#For 47 and 26 CD4 counts were not available in dead and survived patients respectively.
doi:10.1371/journal.pone.0021008.t005
Table 6. Association of treatment related risk factors with TB treatment outcome and with survival status.
Factors
Treatment outcome
unfavourable v/s favourable
Survival status
Dead v/s Survived
aOR 95% CI P value aOR 95% CI P value
Type of patient
Retreatment/New
4.78 2.12–10.76 0.000 1.94 0.89–4.21 0.093
Disease classification
Pulmonary/Extra pulmonary
1.96 1.02–3.77 0.044 1.82 1.00–3.33 0.050
ART initiation
Not on ART / on ART
4.90 1.85–12.96 0.001 2.80 1.15–6.81 0.023
CPT provision
Not initiated/initiated
2.19 0.90–5.32 0.083 3.46 1.47–8.14 0.004
Prediction 80.8% 76.5%
aOR- Adjusted Odds Ratio, CI – Confidence Interval.
doi:10.1371/journal.pone.0021008.t006
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prior sub optimal therapy is known to be a major contributor to
the development of Multi Drug Resistant (MDR) TB [23].
Normally MDR confers a high mortality rate for both HIV
seropositive and seronegative patients [24,30]. In addition, HIV
infected patients having MDR TB were twice as likely to die than
those who did not have MDR TB [31].
Non initiation of ART has also emerged as a risk factor for
‘unfavourable’ treatment outcome. Appropriate time of ART
initiation, while on TB treatment has been an issue of dispute. Of
the 157 (56%0 patients in the study group initiated on ART ; 19%
were already on ART and only 6% were initiated within 15 days of
TB treatment as per NACO guidelines. Studies have demonstrated
that simultaneous use of ART with anti TB treatment significantly
reduces the risk of death both short and long term [32,33]. Hence,
the pros and cons of early initiation of ART especially for those with
advanced immunosuppression should be assessed carefully.
Although, extra pulmonary tuberculosis is generally associated
with higher degree of immunosuppression, pulmonary tuber-
culosis has emerged as a risk factor for ‘unfavourable outcome’ in
our study as well as in Kenya in contrast to other report where it
was not so [34].
A high mortality (30%) observed in our study has also been
reported in several studies among HIV infected TB patients
[13,18,24,27,35]. Nearly four times higher death rates were
observed in HIV positive compared to HIV negative TB patients
during the first six months after treatment initiation in a prospective
cohort study in Kenya [15]. The median survival time was 7.3
months in our study which was similar to that reported from San
Francisco (7.4 months) [24] and Peru (9 months) [34]. The higher
mortality in HIV associated tuberculosis could be mostly due to
other OIs, which occur in the presence of profound immunosup-
pression as also seen in our study group wherein the median CD4
count was 117/mm
3. Tuberculosis is known to accelerate HIV
disease progression because of production of cytokines like TNF-a,
which increases viral replication.
PatientswithpulmonaryTB, retreatmentcases,withtreatmentirregularity,not
receivingART&CPTandthosewithunfavourableTBtreatmentoutcome were
the factors associated with mortality in the univariate analysis.
However in the logistic regression analysis ‘non initiation of
ART’ and of ‘CPT’ emerged as strong risk factors for mortality.
Surprisingly, lower CD4 count of ,200/mm
3 indicating advanced
immunosuppression was not associated with mortality in our study
is reported by others too, possibly because TB itself may enhance
the progression of HIV infection [15,17,34,36,37]. This is in
contradiction with the higher deaths reported among patients with
baseline CD4 counts of ,200/mm
3 [32,35]. The probable
explanation for this difference could be the non availability of
CD4 count for a substantial proportion (56%) of dead patients.
Proportion of patients with irregular drug intake and those
having unfavourable TB treatment outcome particularly, defaults
were higher in the ‘dead’ group. Receipt of inadequate anti TB
treatment has shown to increase the risk of death and is consistent
with other reports [23,38].
There is adequate data to show that patients with TB and HIV
who did not receive ART had a short survival time [31,32,39].
The reduction in the risk of death with addition of ART has been
reported from Peru and San Francisco [34,40]. Despite the
apparent benefit associated with ART only 56% of the HIV
infected TB patients in our study and 44% in San Francisco
received ART. Although, deferring ART simplifies the manage-
ment of two diseases, the results provide compelling evidence to
warrant initiation of ART along with TB treatment. Unfortunate-
ly, most HIV infected TB patients in many developing countries
still cannot access ART primarily due to economic barriers and
limited coverage. If ART is deferred another OI may superimpose
and accelerate HIV disease progression [41]. The importance of
chemoprophylactic treatment to prevent other OIs may also play a
significant role in avoiding deaths particularly when the access to
ART is limited as in developing countries [39].
Even in accordance to NACO ART guidelines, 80% of the
eligible TB patients with CD4 count available received ART in
our study [42]. The important contributing factor for this gap
could be the provision of ART from a single centre situated in a
tertiary health care setting in the district during the study period.
However, expansion of ART facilities is now under progress
particularly in high HIV prevalent areas. TB treatment outcomes
did not differ significantly among those with CD4 count of .350/
mm
3 compared to those with ,350/mm
3 and over 94% of
patients with CD4 count available were anyway eligible for ART
as per current National guidelines. Moreover, ‘non initiation of ART’
was significantly associated with mortality. This makes a strong
case for changing the current National guidelines to align with
WHO recommendation that all HIV infected TB patients should
be initiated on ART irrespective of CD4 counts.
Being a retrospective study conducted under programme
conditions and based on the information from RNTCP and NACP
programme records and patient interviews, was subjected to certain
limitations. Firstly, some of the important potential factors including
clinical manifestations, radiological presentation, drug susceptibility
status and occurrence of OIs which are likely to influence the TB
treatmentoutcome orsurvivalstatuscouldnotbestudied.Secondly,
despite repeated efforts by the study team, the CD4 cell count was
not available for a substantial proportion (26%) of patients from the
ART records, particularly, for those defaulted and dead. This could
have added to the knowledge on the association between
immunosuppression and unfavourable outcome. Finally, the exact
cause of death could not be ascertained in many patients as majority
of the deaths occurred outside the hospital and relevant records for
the same were not available with the informants.
Conclusion
Despite the availability of effective treatment for TB and HIV,
the high mortality observed in the cohort is a matter of concern
and needs early intervention. The study highlights the importance
of preventing premature cessation of anti-TB treatment leading to
default wherein the proportion of death was high. Non initiation of
ART has emerged as a high risk factor for unfavourable treatment
outcome as well as for overall mortality. Also, CPT to prevent
other OIs may play a role in avoiding deaths particularly, when
ART is not initiated. These findings underscore the importance of
access and availability of ART services as a priority, especially in
high HIV prevalent areas. This also makes a strong case for
reconsidering current programme guidelines on ART initiation to
make it in line with WHO recommendation of initiating ART to
all TB patients irrespective of CD4 count.
Treatment with standard anti TB regimens using DOTS could
be effective in improving the survival and quality of life of patients
with HIV and TB, provided there is concomitant ART to prevent
continued immunological deterioration and progression of HIV.
More Studies are needed to assess the efficacy of SSC intermittent
regimen and their long term outcome, particularly, mortality and
relapses.
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